Viridian Therapeutics, Inc./DE (VRDN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 63.79M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 816.54M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $63.79M | (m) | $816.54M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $51.80M | (m) | $585.84M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $70.70M | (m) | $662.27M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $50.70M | (m) | $321.25M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $52.59M | (m) | $446.03M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $33.73M | (m) | $520.42M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $47.87M | (m) | $617.99M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $41.36M | (m) | $552.92M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $36.76M | (m) | $463.70M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $26.13M | (m) | $521.55M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $26.64M | (m) | $374.54M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $23.25M | (m) | $201.41M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $28.66M | (m) | $247.21M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $29.59M | (m) | $285.34M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $33.35M | (m) | $268.97M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $25.21M | (m) | $87.11M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $21.39M | (m) | $129.91M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $14.39M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $13.64M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $14.34M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $16.83M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $16.44M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $10.67M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $7.56M | (m) | (m) | $57.00K | (m) | (m) |
| 2020-06-30 | (m) | $6.72M | (m) | (m) | $248.00K | (m) | (m) |
| 2020-03-31 | (m) | $8.66M | (m) | (m) | $4.00K | (m) | (m) |
| 2019-12-31 | (m) | $10.18M | (m) | (m) | $108.00K | (m) | (m) |
| 2019-09-30 | (m) | $10.38M | $24.86M | (m) | $979.00K | (m) | (m) |
| 2019-06-30 | (m) | $9.15M | $24.01M | (m) | $325.00K | (m) | (m) |
| 2019-03-31 | (m) | $6.86M | $18.20M | (m) | $6.00K | (m) | (m) |
| 2018-12-31 | (m) | $6.73M | $32.61M | (m) | $24.00K | (m) | (m) |
| 2018-09-30 | (m) | $6.83M | $31.70M | (m) | $1.38M | (m) | (m) |
| 2018-06-30 | (m) | $4.28M | $43.40M | (m) | $1.20M | (m) | (m) |
| 2018-03-31 | (m) | $4.14M | $78.10M | (m) | $4.81M | (m) | (m) |
| 2017-12-31 | (m) | $3.90M | $47.44M | (m) | $1.46M | (m) | (m) |
| 2017-09-30 | (m) | $6.53M | $42.80M | (m) | $635.00K | (m) | (m) |
| 2017-06-30 | (m) | $6.63M | $46.34M | (m) | $539.00K | (m) | (m) |
| 2017-03-31 | (m) | $7.28M | $54.27M | (m) | $277.00K | (m) | (m) |
| 2016-12-31 | (m) | $4.58M | $3.34M | (m) | $524.00K | $64.00K | (m) |
| 2016-09-30 | (m) | $2.85M | $5.35M | (m) | $733.00K | $62.00K | (m) |
| 2016-06-30 | (m) | $2.60M | $6.50M | (m) | $658.00K | $213.00K | (m) |
| 2016-03-31 | (m) | $2.44M | $8.56M | (m) | $490.00K | $269.00K | (m) |
| 2015-12-31 | (m) | $2.47M | $10.83M | (m) | $394.00K | $187.00K | (m) |
| 2015-09-30 | (m) | $2.11M | $12.12M | (m) | $547.00K | $364.00K | (m) |
| 2015-06-30 | (m) | $2.08M | (m) | (m) | $581.00K | $536.00K | (m) |
| 2015-03-31 | (m) | $2.50M | (m) | (m) | $598.00K | $330.00K | (m) |
| 2014-12-31 | (m) | $1.99M | (m) | (m) | $1.09M | $179.00K | (m) |
| 2014-09-30 | (m) | $2.00M | $6.39M | (m) | $1.55M | $232.06K | (m) |
| 2014-06-30 | (m) | $2.14M | $7.70M | (m) | $1.36M | $193.14K | (m) |
| 2013-12-31 | (m) | $27.30M | $209.35K | (m) | $994.01K | $356.64K | (m) |
| 2013-09-30 | (m) | (m) | $226.25K | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $247.06K | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $112.53K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |